熊去氧胆酸联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝炎疗效观察  

Clinic efficacy of ursodeoxycholic acid combined with polyene phosphatidylcholine on non-alcoholic steatohepatitis

作　　者：占国清[1] 谭华炳[1] 李芳[1] 李儒贵[1] 李刚[1] 郭鹏[1] 张薇薇[1] 

机构地区：[1]湖北医药学院附属人民医院肝病研究所,湖北十堰442000

出　　处：《临床消化病杂志》2015年第1期5-8,共4页Chinese Journal of Clinical Gastroenterology

摘　　要：[目的]观察熊去氧胆酸(UDCA)联合多烯磷脂酰胆碱(PPC)治疗非酒精性脂肪性肝炎(NASH)的临床疗效。[方法]85例NASH患者被随机分为2组,观察组(45例)给予口服UDCA胶囊250mg和PPC片465mg,3次/d;对照组(40例)给予口服PPC片465mg,3次/d;2组疗程均为3个月。观察2组治疗前后肝功能、血脂及B超下脂肪肝影像变化。[结果]观察组总有效率为75.6%,明显高于对照组的52.5%(P<0.05);治疗后观察组谷草转氨酶、谷丙转氨酶、总胆红素和谷氨酰转肽酶分别为(36.0±15.2)U/L、(32.5±14.5)U/L、(15.6±6.0)!mol/L和(67.5±23.5)U/L,明显低于对照组的(45.6±20.5)U/L、(42.0±17.5)U/L、(21.5±7.2)!mol/L、(90.3±35.2)U/L(P<0.05或P<0.01);观察组总胆固醇、三酰甘油分别为(1.7±0.9)mmol/L、(4.0±0.6)mmol/L,明显低于对照组的(2.1±1.0)mmol/L、(4.4±0.7)mmol/L(P<0.05或P<0.01),2组高密度脂蛋白胆固醇、低密度脂蛋白胆固醇比较差异无统计学意义(P>0.05);观察组和对照组治疗后脂肪肝程度均较治疗前有显著改善(P<0.01或P<0.05),但2组间比较差异无统计学意义(P>0.05)。[结论]UDCA联合PPC治疗NASH有较好的疗效。[Objective]To observe the clinic efficacy of ursodeoxycholic acid（UDCA）combined with polyene phosphatidylcholine（PPC）in the treatment of non-alcoholic steatohepatitis（NASH）.[Methods]Eighty-five patients with NASH were randomly divided into two groups.The observation group（n=45）received UDCA capsules 250 mg and PPC tablets 456 mg by oral three times daily,the control group（n=40）was treated with PPC tablets 456 mg by oral three times daily.The regimen lasted for three months.The changes of liver function,blood lipid and fatty liver image under B ultrasound in the two groups were observed before and after treatment.[Results]The total effective rates of observation group was 75.6%,which was higher than 52.5% of control group（P〈0.05）.After treatment,AST,ALT,TBil and GGT in observation group were（36.0±15.2）U/L,（32.5±14.5）U/L,（15.6±6.0）μmol/L and（67.5±23.5）U/L seperately,which was lower than（45.6±20.5）U/L,（42.0±17.5）U/L,（21.5±7.2）μmol/L and（90.3±35.2）U/L in control group（P〈0.05 or P〈0.01）.TG,TC in observation group were（1.7±0.9）mmol/L,（4.0±0.6）mmol/L,which was lower than（2.1±1.0）mmol/L,（4.4±0.7）mmol/L in control group（P〈0.05 or P〈0.01）.The two groups had no statistically significant difference in HDL-C,LDL-C（P〈0.05）.Fatty liver under B ultrasound in observation group and the control group were obviously improved after treatment（P〈0.05 or P〈0.01）,but there was no significant difference between these two groups（P〉0.05）.[Conclusion]Ursodeoxycholic acid combined with polyene phosphatidylcholine has the good clinical efficacy for the treatment of patients with NASH.

关 键 词：非酒精性脂肪性肝炎 熊去氧胆酸 多烯磷脂酰胆碱 治疗 

分 类 号：R575.1[医药卫生—消化系统]